LUND, SWEDEN--(Marketwire - September 06, 2012) - Active Biotech (NASDAQ OMX NORDIC: ACTI) is
scheduled to present at the Rodman & Renshaw Annual Global Investment
held September 9-11, 2012 in New York, USA. During the presentation, an
regarding Active Biotech's development programs will be provided.
The presentation will include projects in Phase III; laquinimod, a novel
immunomodulatory drug for the treatment of multiple sclerosis, licensed to
Pharmaceutical Industries Ltd, the prostate cancer project TASQ, in
development with Ipsen as well as ANYARA, Active Biotech's novel concept
tumor therapy in a Phase III study for renal cell cancer. Also, the
57-57 and the pre-clinical ISI project will be presented.
The audio and slide presentation will be webcasted live and can be accessed
the Active Biotech web site. To access the live and replay presentations
go to - www.activebiotech.com.
The presentation will take place on September 11, at 12:05 pm US
Daylight Time/ 18:05 Central European Summer Time.
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company
focus on autoimmune/inflammatory diseases and cancer. Projects in or
pivotal phase are laquinimod, an orally administered small molecule with
immunomodulatory properties for the treatment of multiple sclerosis, TASQ
prostate cancer as well as ANYARA for use in cancer targeted therapy,
of renal cell cancer. In addition, laquinimod is in Phase II development
Crohn's and Lupus. An additional project in clinical development is the
administered compound 57-57 for Systemic Sclerosis. Please
www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is obligated to publish the information contained in this
release in accordance with the Swedish Securities Market Act. This
was provided to the media for publication 8:30 a.m. CET on September 6, 2012.
Active Biotech to Present at the Rodman & Renshaw Annual Global Inv:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE